Literature DB >> 20833118

Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation.

Paolo Caraceni1, Luca Santi, Federica Mirici, Giancarlo Montanari, Vittoria Bevilacqua, Antonio Daniele Pinna, Mauro Bernardi.   

Abstract

BACKGROUND/AIMS: Terlipressin plus albumin is first-line treatment for hepatorenal syndrome (HRS). Therapy lasts from a few days to two weeks, whereas the efficacy and safety of long-term administration remain unsettled.
METHODS: We describe our experience of prolonged terlipressin and albumin treatment as a bridge to liver transplantation in three patients with cirrhosis and recurrent HRS.
RESULTS: The length of treatment ranged from 62 days to eight months. Attempts to suspend terlipressin or to switch treatment to midodrine plus octreotide were consistently associated with a deterioration of serum creatinine and oliguria. No major side-effects were observed. All patients were transplanted, but two died from peri-operative complications.
CONCLUSIONS: These clinical cases suggest that long-term terlipressin administration in selected patients with recurrent HRS awaiting liver transplantation may represent an option to prevent irreversible renal failure and the need for dialysis until an organ becomes available.
Copyright © 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20833118     DOI: 10.1016/j.dld.2010.08.001

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  9 in total

1.  A Novel prognostic scoring system to predict 3-month mortality risk in patients with acute-on-chronic liver failure in hepatitis B: a retrospective cohort study.

Authors:  Yu-Bao Zheng; Shi-Bin Xie; Dong-Ying Xie; Liang Peng; Zi-Ying Lei; Hong Deng; Bin-Liang Lin; Chao-Shuang Lin; Zhi-Xin Zhao; Wei-Min Ke; Zhi-Liang Gao
Journal:  Hepatol Int       Date:  2012-01-29       Impact factor: 6.047

Review 2.  Acute kidney injury in acute on chronic liver failure.

Authors:  Rakhi Maiwall; S K Sarin; Richard Moreau
Journal:  Hepatol Int       Date:  2015-10-15       Impact factor: 6.047

3.  Development of a rat model of D-galactosamine/lipopolysaccharide induced hepatorenal syndrome.

Authors:  Jing-Bo Wang; Hai-Tao Wang; Lu-Ping Li; Ying-Chun Yan; Wei Wang; Jing-Yang Liu; Yi-Tong Zhao; Wei-Shu Gao; Ming-Xiang Zhang
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

Review 4.  Outcomes of liver transplantation in patients with hepatorenal syndrome.

Authors:  Rohan M Modi; Nishi Patel; Sherif N Metwally; Khalid Mumtaz
Journal:  World J Hepatol       Date:  2016-08-28

Review 5.  Renal dysfunction in patients with cirrhosis: Where do we stand?

Authors:  Chrysoula Pipili; Evangelos Cholongitas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-08-06

Review 6.  Hepatorenal syndrome.

Authors:  Jan Lata
Journal:  World J Gastroenterol       Date:  2012-09-28       Impact factor: 5.742

7.  Management and outcome in hepatorenal syndrome: need for renal replacement therapy in non-transplanted patients.

Authors:  Achuthan Sourianarayanane; Rupesh Raina; Gaurav Garg; Arthur J McCullough; Robert S O'Shea
Journal:  Int Urol Nephrol       Date:  2013-08-10       Impact factor: 2.370

Review 8.  Human albumin in the management of complications of liver cirrhosis.

Authors:  Mauro Bernardi; Caterina Maggioli; Giacomo Zaccherini
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

9.  Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis.

Authors:  Francesco Salerno; Roberta J Navickis; Mahlon M Wilkes
Journal:  BMC Gastroenterol       Date:  2015-11-25       Impact factor: 3.067

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.